Literature DB >> 21889224

The maximum standardized uptake value (SUVmax) on FDG-PET is a strong predictor of local recurrence for localized non-small-cell lung cancer after stereotactic body radiotherapy (SBRT).

Atsuya Takeda1, Noriko Yokosuka, Toshio Ohashi, Etsuo Kunieda, Hirofumi Fujii, Yousuke Aoki, Naoko Sanuki, Naoyoshi Koike, Yukihiko Ozawa.   

Abstract

BACKGROUND: The maximum standardized uptake value (SUVmax) of FDG-PET may predict local recurrence for localized non-small-cell lung cancer (NSCLC) after stereotactic body radiotherapy (SBRT).
METHODS: Among 195 localized NSCLCs that were treated with total doses of either 40Gy or 50Gy in 5 SBRT fractions, we reviewed those patients who underwent pre-treatment FDG-PET using a single scanner for staging. Local control rates (LCRs) were obtained by the Kaplan-Meier method and a log-rank test. Prognostic significance was assessed by univariate and multivariate analyses.
RESULTS: A total of 95 patients with 97 lesions were eligible. Median follow-up was 16.0months (range: 6.0-46.3months). Local recurrences occurred in 9 lesions. By multivariate analysis, only the SUVmax of a primary tumor was a significant predictor (p=0.002). Two years LCRs for lower SUVmax (<6.0; n=78) and higher SUVmax (⩾6; n=19) were 93% and 42%, respectively. In subgroups with T1b and T2, LCRs were significantly better for lower SUVmax than for higher SUVmax (p<0.0005 and p<0.01). In both subgroups that received 40Gy and 50Gy, LCRs were also significantly better for lower SUVmax than for higher SUVmax (p<0.001 and p<0.01).
CONCLUSIONS: SUVmax was the strongest predictor for local recurrence. A high SUVmax may be considered for dose escalation to improve local control. Additional follow-up is needed to determine if SUVmax is correlated with regional recurrence, distant metastasis, and survival.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21889224     DOI: 10.1016/j.radonc.2011.08.008

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  36 in total

1.  A comparison study of dual-energy spectral CT and 18F-FDG PET/CT in primary tumors and lymph nodes of lung cancer.

Authors:  Osman Kupik; Yavuz Metin; Gülnihan Eren; Nurgul Orhan Metin; Medeni Arpa
Journal:  Diagn Interv Radiol       Date:  2021-03       Impact factor: 2.630

2.  Effects of the recurrence pattern on patient survival following SABR for stage I lung cancer.

Authors:  Elisabeth Weiss; Xiaoyan Deng; Nitai Mukhopadhyay; Nuzhat Jan
Journal:  Acta Oncol       Date:  2020-01-12       Impact factor: 4.089

Review 3.  Pulmonary imaging after stereotactic radiotherapy-does RECIST still apply?

Authors:  Sarah A Mattonen; Aaron D Ward; David A Palma
Journal:  Br J Radiol       Date:  2016-06-20       Impact factor: 3.039

4.  Evaluation of response after SBRT for liver tumors.

Authors:  Raphael Tétreau; Carmen Llacer; Olivier Riou; Emmanuel Deshayes
Journal:  Rep Pract Oncol Radiother       Date:  2015-12-30

5.  Spatially resolved regression analysis of pre-treatment FDG, FLT and Cu-ATSM PET from post-treatment FDG PET: an exploratory study.

Authors:  Stephen R Bowen; Richard J Chappell; Søren M Bentzen; Michael A Deveau; Lisa J Forrest; Robert Jeraj
Journal:  Radiother Oncol       Date:  2012-06-08       Impact factor: 6.280

6.  FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer.

Authors:  Zachary A Kohutek; Abraham J Wu; Zhigang Zhang; Amanda Foster; Shaun U Din; Ellen D Yorke; Robert Downey; Kenneth E Rosenzweig; Wolfgang A Weber; Andreas Rimner
Journal:  Lung Cancer       Date:  2015-05-28       Impact factor: 5.705

7.  Factors affecting the local control of stereotactic body radiotherapy for lung tumors including primary lung cancer and metastatic lung tumors.

Authors:  Yasushi Hamamoto; Masaaki Kataoka; Motohiro Yamashita; Naoyuki Nogami; Yoshifumi Sugawara; Toshiyuki Kozuki; Shigeki Sawada; Hiroshi Suehisa; Syuichi Shinohara; Naomi Nakajima; Tetsu Shinkai
Journal:  Jpn J Radiol       Date:  2012-03-27       Impact factor: 2.374

8.  Maximum standardized uptake value on FDG-PET predicts survival in stage I non-small cell lung cancer following carbon ion radiotherapy.

Authors:  Katsuyuki Shirai; Takanori Abe; Jun-Ichi Saitoh; Tatsuji Mizukami; Daisuke Irie; Yosuke Takakusagi; Shintaro Shiba; Naoko Okano; Takeshi Ebara; Tatsuya Ohno; Takashi Nakano
Journal:  Oncol Lett       Date:  2017-03-29       Impact factor: 2.967

9.  Can high-risk CT features suggest local recurrence after stereotactic body radiation therapy for lung cancer? A systematic review and meta-analysis.

Authors:  Tae-Hyung Kim; Sungmin Woo; Darragh F Halpenny; Yeon Joo Kim; Soon Ho Yoon; Chong Hyun Suh
Journal:  Eur J Radiol       Date:  2020-04-07       Impact factor: 3.528

10.  Stability of FDG-PET Radiomics features: an integrated analysis of test-retest and inter-observer variability.

Authors:  Ralph T H Leijenaar; Sara Carvalho; Emmanuel Rios Velazquez; Wouter J C van Elmpt; Chintan Parmar; Otto S Hoekstra; Corneline J Hoekstra; Ronald Boellaard; André L A J Dekker; Robert J Gillies; Hugo J W L Aerts; Philippe Lambin
Journal:  Acta Oncol       Date:  2013-09-09       Impact factor: 4.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.